Oral lichenoid eruption secondary to imatinib (Glivec®)

Journal of Dermatological Treatment

Volumn 15, Issue 4, 2004, Pages 253-255

  Ena, Pasquale ^a,b   Chiarolini, F ^a   Siddi, G M ^a   Cossu, A ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b NONE   (Italy)

Author keywords

Gastrointestinal stromal tumour; Imatinib side effects; Oral lichen planus; Oral lichenoid eruption

Indexed keywords

BIOMEDICAL AND DENTAL MATERIALS; CORTICOSTEROID; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; GOLD; IMATINIB; IMMUNOMODULATING AGENT; MERCURY; OMEPRAZOLE;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; DERMOEPIDERMAL JUNCTION; DRUG ERUPTION; EOSINOPHIL; ERYTHEMA; GASTROINTESTINAL STROMAL TUMOR; HISTOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LICHEN PLANUS; LICHENOID ERUPTION; LYMPHOCYTIC INFILTRATION; MALE; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DISEASE; SKIN ULCER;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; MOUTH DISEASES; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 3543016166     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/09546630410015556     Document Type: Article

References (15)

1. Demetri GD, von Mehren M, Blanke CD, et al, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 347: 472-80.
2. Drummond A, Micallef-Eynaud P, Douglas WS, et al, A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (sti 571, Glivec®). Br J Haematol (2003) 120: 911-13.
3. Lim DS, Muir J, Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology (2002) 205: 169-71.
4. Dega H, Le Cleach L, Lichen plan et dermatoses lichénoides. Encyclopédie Médico-Chirurgicale Dermatologie. Elsevier: Paris. (1999) 98-525-A-10.
5. McCartan B, McCeary CE, Oral lichenoid drug eruptions. Oral Dis (1997) 3: 58-63.
6. Van den Haute V, Antoine JL, Lachapelle JM, Histopathological discriminant criteria between lichenoid drug eruptions and idiopathic lichen planus: a retrospective study on selected samples. Dermatologica (1989) 179: 10-13.
7. Hamburger J, Potts AJC, Non-steroidal and inflammatory drugs and oral lichenoid reactions. BMJ (1983) 287: 1258.
8. Oliver GF, Winkelmann RK, Muller SA, Lichenoid dermatitis: a clinico-pathologic and immunopathologic review of sixty-two cases. J Am Acad Dermatol (1989) 21: 284-92.
9. De Silva CM, Reid R, Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and target cancer therapy with imatinib. Pathol Oncol Res (2003) 9: 13-19.
10. Brouard MC, Prins C, Mach-Pascual S, Saurat JH, Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology (2001) 203: 57-9.
11. Konstantopoulos K, Papadogianni A, Dimopoulou M, et al, Pityriasis rosca associated with imatinib (STI571, Gleevec). Dermatology (2002) 205: 172-3.
12. Hsiao L, Chung H, Lin J, et al, Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol (2002) 117: 620-2.
13. Banka N, Aljurf M, Hamadah I, Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign. Dermatology (2003) 207: 329-30.
14. Gombos F, Serpico R, Immunopatologia orale. Piccin: Padova, 1999: 19-22.
15. Boisnic S, Ouhayoun JP, Branchet MC, et al, Alteration of cytokeratin expression in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1995) 79: 207-15.